CytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. The company reported quarterly sales of $1.418 million which
CytomX lost less money than expected per share, which is good, but their sales were way smaller than investors hoped for. When a company makes much less money than predicted, it's a warning sign that things might not be going as planned.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.